Caribou Biosciences Inc
CRBU2.086USD
+0.136+6.98%
Market hours （ET）Quotes delayed by 15 min
194.03MMarket Cap
LossP/E TTM
More Details of Caribou Biosciences Inc Company
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Company Info
Ticker SymbolCRBU
Company nameCaribou Biosciences Inc
IPO dateJul 23, 2021
CEODr. Rachel E. Haurwitz, Ph.D.
Number of employees147
Security typeOrdinary Share
Fiscal year-endJul 23
Address2929 7Th Street, Ste 120
CityBERKELEY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94710
Phone15109826030
Websitehttps://www.cariboubio.com/
Ticker SymbolCRBU
IPO dateJul 23, 2021
CEODr. Rachel E. Haurwitz, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-7.13%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
Dr. Tina Albertson, M.D., Ph.D.
Dr. Tina Albertson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Mr. Tim Kelly
Mr. Tim Kelly
Chief Technology Officer
Chief Technology Officer
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-7.13%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
Dr. Tina Albertson, M.D., Ph.D.
Dr. Tina Albertson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
2.22M
94.52%
Rest of world
129.00K
5.48%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.17%
Pfizer Inc
5.04%
The Vanguard Group, Inc.
4.86%
Haurwitz (Rachel E. Ph.D.)
3.70%
Kynam Capital Management LP
3.52%
Other
76.71%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.17%
Pfizer Inc
5.04%
The Vanguard Group, Inc.
4.86%
Haurwitz (Rachel E. Ph.D.)
3.70%
Kynam Capital Management LP
3.52%
Other
76.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.43%
Hedge Fund
13.59%
Investment Advisor/Hedge Fund
11.64%
Corporation
5.04%
Individual Investor
4.80%
Research Firm
3.27%
Private Equity
0.85%
Pension Fund
0.20%
Bank and Trust
0.10%
Other
37.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
336
58.49M
62.89%
-33.57M
2025Q1
357
59.01M
63.59%
-33.82M
2024Q4
351
66.38M
73.32%
-26.01M
2024Q3
346
65.41M
72.38%
-24.69M
2024Q2
342
66.38M
73.55%
-23.41M
2024Q1
328
78.97M
90.08%
-7.22M
2023Q4
321
82.70M
97.59%
-4.14M
2023Q3
317
84.62M
100.71%
+22.26M
2023Q2
303
56.44M
92.00%
-2.65M
2023Q1
293
52.85M
86.27%
-4.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.74M
6.17%
-215.25K
-3.62%
Mar 31, 2025
Pfizer Inc
4.69M
5.04%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
4.52M
4.86%
-43.41K
-0.95%
Mar 31, 2025
Haurwitz (Rachel E. Ph.D.)
3.44M
3.7%
-87.08K
-2.47%
Apr 22, 2025
Kynam Capital Management LP
3.27M
3.52%
+863.00K
+35.87%
Mar 31, 2025
PFM Health Sciences, LP
2.51M
2.69%
-1.37M
-35.34%
Mar 31, 2025
Two Sigma Investments, LP
2.49M
2.68%
-100.90K
-3.90%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
2.35M
2.53%
+238.31K
+11.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.05M
2.21%
+81.53K
+4.13%
Mar 31, 2025
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH
2.00M
2.15%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AXS Green Alpha ETF
0.64%
WisdomTree BioRevolution Fund
0.31%
Avantis US Equity ETF
0%
Goldman Sachs Innovate Equity ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Schwab U.S. Broad Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
View more
AXS Green Alpha ETF
Proportion0.64%
WisdomTree BioRevolution Fund
Proportion0.31%
Avantis US Equity ETF
Proportion0%
Goldman Sachs Innovate Equity ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
